Real‐world prophylactic usage of recombinant factor IX Fc in Sweden: A report from the Swedish National Registry for bleeding disorders.

Autor: Olsson, Anna, Westesson, Linda Myrin, Baghaei, Fariba, Holmström, Margareta, Olsson, Elsa, Magnusson, Maria, Ranta, Susanna, Astermark, Jan, Andersson, Nadine G., Thanner, Judith, Szamosi, Johan, Daoura, Loudin, Sennfält, Karin
Předmět:
Zdroj: Haemophilia; Jan2023, Vol. 29 Issue 1, p377-381, 5p, 1 Chart, 1 Graph
Abstrakt: Overall, real-world data from Sweden suggest that HB patients aged >=13 years who switch from prophylactic SHL FIX to EHL rFIXFc have reduced factor consumption and injection frequency, with a similar or improved level of bleed protection. Moreover, a within-patient comparison was performed for patients who switched from SHL FIX to EHL rFIXFc with >=6 months of documented prophylactic SHL FIX and EHL rFIXFc treatment, pre- and post-switch, respectively. Nineteen patients had >=6 months of documented prophylactic SHL FIX and EHL rFIXFc treatment pre- and post-switch, respectively, enabling a within-patient comparison. Most patients (66.7%; I n i = 68) received individualised prophylaxis (SHL FIX [ I n i = 33] and EHL rFIXFc [ I n i = 35]); the remaining patients either received on-demand treatment (SHL FIX [ I n i = 16] and EHL rFIXFc [ I n i = 4]) or had missing treatment regimen data ( I n i = 15). [Extracted from the article]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje